Skip to main content

Advertisement

Table 5 Second line therapies in advanced PDAC

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Regimens Phase Patients mPFS (ms) mOS (ms) OS 6-ms % DCR % PR % Ref
FOLFIRINOX Ret 22 5.4 8.5 n.a. 63 19 [32] 2011
FOLFIRINOX Ret 18 2.8 8.4 44.4 55.6 27.8 [33] 2013
Nab-Paclitaxel II 19 1.7 7.3 58 37 5 [31] 2012
FOLFIRI II 50 3.2 5.0 32 36 8 [18] 2012
Capecitabine/Docetaxel II 43 3.7 5.3 n.a. 73 14 [34] 2014
mFOLFOX II 30 1.5 3.7 30 17 7 [28] 2009
FOLFIRI   31 2.1 4.2 27 23 0
OFF III 23 n.a. 4.8 n.a. n.a. n.a. [8] 2011
BSC 23 2.3
OFF III 76 2.9 5.9 n.a. n.a. n.a. [9] 2014
FF 84 2.0 3.3
Xelox II 39 2.5 5.8 44 28.6 2.6 [35] 2008
Docetaxel Ret 17 2 4 n.a. 35 6 [15] 2010
Nal-Iri II 40 2.4 5.2 42.5 50 7.5 [27] 2013
Nal-Iri/5-FU/LV III 417 3.1 6.1 n.a. n.a. n.a. [10] 2014
5-FU/LV 1.5 4.2
GEMOX II 33 4.2 6 n.a. 61.3 22.6 [36] 2006
Vatalanib II 67 2 n.a. 29 31 3 [37] 2014
DocOx II 44 1.8 10.1 56.8 48 15.9  
  1. mPFS median progression free survival time, mOS median overall survival time, Ref reference, Ret Retrospective, ms months, DCR disease control rate, PR partial remission, ms months, OFF oxaliplatin, folinic acid, fluorouracil, LV leucovorine, 5-FU 5-fluorouracil, Nab-Paclitaxel nanoalbumine bound pacitaxel, Nal-Iri nanoliposomal irinotecan, FOLFIRI fluorouracil, leucovorine, irinotecan, FOLFOX fluorouracil, leucovorine, oxaliplatin, FOLFIRINOX fluorouracil, leucovorine, irinotecan, oxaliplatin, DocOx docetaxel oxaliplatin, n.a. not applicable, Ref Reference and publication date